Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study
CONCLUSION: This study reports a prevalence of 33.1% of ADEs among patients on DTG-based regimen. The most commonly experienced ADE was allergy. Male sex, early HIV disease stage at entry into care and detectable viral load at initiation of DTG-based regimen were significantly associated with ADEs. It is crucial to actively monitor patients with these characteristics for ADEs.PMID:35366917 | PMC:PMC8976982 | DOI:10.1186/s12981-022-00442-7
Source: AIDS Research and Therapy - April 3, 2022 Category: Infectious Diseases Authors: Angella Namulindwa John Hans Wasswa Winnie Muyindike Robert Tamukong Joseph Oloro Source Type: research
Antibiotic desensitization as a potential tool in antimicrobial stewardship programs: retrospective data analysis and systematic literature review
CONCLUSIONS: : Antibiotic desensitization strategies should be considered a safe and effective tool that can be included in ASP for patients with a high risk of or confirmed allergy to penicillin.PMID:36069242 | DOI:10.1080/14787210.2022.2122443
Source: Expert Review of Anti-Infective Therapy - September 7, 2022 Category: Infectious Diseases Authors: Alicia Rodr íguez-Alarcón Jaime Barcel ó-Vidal Daniel Echeverr ía-Esnal Luisa Sorli Roberto G üerri-Fernández Sof ía Martina Ramis Fernández Adela Benitez-Cano Elena Sendra Inmaculada L ópez Montesinos Estela Membrilla-Fern ández Olivia Ferr án Source Type: research
The effectiveness of interventions that support penicillin allergy assessment and de-labelling of adult and paediatric patients by non-allergy specialists: A systematic review and meta-analysis
PADL by non-allergists is efficacious and safe. The proportion of assessed patients who can be de-labelled increases with complexity of testing method, but substantial numbers can be de-labelled without skin testing.
Source: International Journal of Infectious Diseases - November 26, 2022 Category: Infectious Diseases Authors: Neil Powell, Jennie Stephens, Declan Kohl, Rhys Owens, Shadia Ahmed, Crispin Musicha, Mathew Upton, Bridie Kent, Sarah Tonkin-Crine, Jonathan Sandoe Source Type: research
Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine
CONCLUSIONS: These results together show that prior exposure and sex interact to shape early innate responses that then impact subsequent adaptive immune phenotypes.FUNDING: Intramural Research Program of the NIH, the National Institute of Allergy and Infectious Diseases, and other institutes supporting the Trans-NIH Center for Human Immunology, Autoimmunity, and Inflammation. The vaccine trial was supported through a clinical trial agreement between the National Institute of Allergy and Infectious Diseases and Sanofi Pasteur. Clinical trial number: NCT01915212.PMID:36648132 | DOI:10.7554/eLife.80652
Source: Herpes - January 17, 2023 Category: Infectious Diseases Authors: Foo Cheung Richard Apps Lesia Dropulic Yuri Kotliarov Jinguo Chen Tristan Jordan Marc Langweiler Julian Candia Angelique Biancotto Kyu Lee Han Nicholas Rachmaninoff Harlan Pietz Kening Wang John S Tsang Jeffrey I Cohen Source Type: research
Cutaneous reactions following COVID-19 vaccination assessed by dermatologists: a single-institutional study in Germany
CONCLUSIONS: It can be assumed that vaccination may trigger immune activation-related reactions especially in those patients predisposed to develop respective skin diseases.PMID:36892192 | DOI:10.1111/ddg.14987
Source: Herpes - March 9, 2023 Category: Infectious Diseases Authors: Rosi Wang Sonja Mathes Carla Claussen Tilo Biedermann Knut Brockow Source Type: research
Could probiotics help HIV patients?
(Journal of Clinical Investigation) In this issue of the Journal of Clinical Investigation, researchers led by Jason Brenchley at the National Institute of Allergy and Infectious Disease, demonstrated that probiotic supplementation improved gut immune function in SIV-infected macaques.
Source: EurekAlert! - Infectious and Emerging Diseases - January 16, 2013 Category: Infectious Diseases Source Type: news
Treatment for novel coronavirus shows promise in early lab tests
(NIH/National Institute of Allergy and Infectious Diseases) National Institutes of Health scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells. These results suggest that the drug combination could be used to treat patients infected with the new coronavirus, but more research is needed to confirm this preliminary finding.
Source: EurekAlert! - Infectious and Emerging Diseases - April 18, 2013 Category: Infectious Diseases Source Type: news
NIH study offers clues to making vaccine for infant respiratory illness
(NIH/National Institute of Allergy and Infectious Diseases) An atomic-level snapshot of a respiratory syncytial virus protein bound to a human antibody represents a leap toward developing a vaccine for a common -- and sometimes very serious -- childhood disease.
Source: EurekAlert! - Infectious and Emerging Diseases - April 25, 2013 Category: Infectious Diseases Source Type: news
Cell response to new coronavirus unveils possible paths to treatments
(NIH/National Institute of Allergy and Infectious Diseases) IH-supported scientists used lab-grown human lung cells to study the cells' response to infection by a novel human coronavirus (called nCoV) and compiled information about which genes are significantly disrupted in early and late stages of infection. The information about host response to nCoV allowed the researchers to predict drugs that might be used to inhibit either the virus itself or the deleterious responses that host cells make in reaction to infection.
Source: EurekAlert! - Infectious and Emerging Diseases - April 30, 2013 Category: Infectious Diseases Source Type: news
